NYSE:CRL - Charles River Laboratories Intl. Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$104.13 -1.55 (-1.47 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$104.13
Today's Range$103.97 - $105.90
52-Week Range$91.47 - $119.05
Volume227,455 shs
Average Volume364,890 shs
Market Capitalization$5.06 billion
P/E Ratio19.68
Dividend YieldN/A
Beta0.69

About Charles River Laboratories Intl. (NYSE:CRL)

Charles River Laboratories Intl. logoCharles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CRL
CUSIP15986410
Phone781-222-6000

Debt

Debt-to-Equity Ratio0.99
Current Ratio2.07
Quick Ratio1.78

Price-To-Earnings

Trailing P/E Ratio19.68
Forward P/E Ratio17.86
P/E Growth1.34

Sales & Book Value

Annual Sales$1.86 billion
Price / Sales2.69
Cash Flow$8.0534 per share
Price / Cash12.93
Book Value$23.85 per share
Price / Book4.37

Profitability

EPS (Most Recent Fiscal Year)$5.27
Net Income$123.35 million
Net Margins6.78%
Return on Equity24.96%
Return on Assets9.02%

Miscellaneous

Employees11,800
Outstanding Shares47,910,000

Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions

What is Charles River Laboratories Intl.'s stock symbol?

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How will Charles River Laboratories Intl.'s stock buyback program work?

Charles River Laboratories Intl. announced that its Board of Directors has approved a stock repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase $150,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's management believes its shares are undervalued.

How were Charles River Laboratories Intl.'s earnings last quarter?

Charles River Laboratories Intl. Inc (NYSE:CRL) posted its quarterly earnings data on Thursday, May, 10th. The medical research company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.26 by $0.12. The medical research company earned $493.97 million during the quarter, compared to analysts' expectations of $480.03 million. Charles River Laboratories Intl. had a return on equity of 24.96% and a net margin of 6.78%. The firm's revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.29 EPS. View Charles River Laboratories Intl.'s Earnings History.

When is Charles River Laboratories Intl.'s next earnings date?

Charles River Laboratories Intl. is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Charles River Laboratories Intl..

What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?

Charles River Laboratories Intl. issued an update on its FY18 earnings guidance on Thursday, May, 10th. The company provided earnings per share guidance of $5.77-5.92 for the period, compared to the Thomson Reuters consensus estimate of $5.71. The company issued revenue guidance of $2.19-2.23 billion (+18-20%), compared to the consensus revenue estimate of $2.15 billion.

What price target have analysts set for CRL?

13 analysts have issued 1-year price objectives for Charles River Laboratories Intl.'s stock. Their forecasts range from $102.00 to $130.00. On average, they expect Charles River Laboratories Intl.'s stock price to reach $115.7692 in the next twelve months. View Analyst Ratings for Charles River Laboratories Intl..

Are investors shorting Charles River Laboratories Intl.?

Charles River Laboratories Intl. saw a decline in short interest during the month of April. As of April 30th, there was short interest totalling 1,285,521 shares, a decline of 39.6% from the April 13th total of 2,126,952 shares. Based on an average daily volume of 269,412 shares, the days-to-cover ratio is currently 4.8 days. Currently, 2.7% of the company's shares are short sold.

Who are some of Charles River Laboratories Intl.'s key competitors?

Who are Charles River Laboratories Intl.'s key executives?

Charles River Laboratories Intl.'s management team includes the folowing people:
  • Mr. James C. Foster, Chairman & CEO (Age 67)
  • Dr. Davide A. Molho, Pres & COO (Age 48)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 52)
  • Mr. David P. Johst, Chief Admin. Officer, Corp. Exec. VP of HR, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 57)

Has Charles River Laboratories Intl. been receiving favorable news coverage?

Media coverage about CRL stock has trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Charles River Laboratories Intl. earned a news sentiment score of 0.14 on Accern's scale. They also assigned media stories about the medical research company an impact score of 46.26 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Charles River Laboratories Intl.'s major shareholders?

Charles River Laboratories Intl.'s stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.76%), Wells Fargo & Company MN (2.63%), Neuberger Berman Group LLC (1.44%), Van Berkom & Associates Inc. (1.29%), Dimensional Fund Advisors LP (1.11%) and Lord Abbett & CO. LLC (0.99%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, Kevin Ma, Online Communications Bdirect, Richard F Wallman, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..

Which major investors are selling Charles River Laboratories Intl. stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prudential Financial Inc., FIL Ltd, JPMorgan Chase & Co., Fisher Asset Management LLC, Hood River Capital Management LLC, Neuberger Berman Group LLC and Victory Capital Management Inc.. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David Ross Smith, Davide Molho, George M Milne Jr, George Massaro, James C Foster, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..

Which major investors are buying Charles River Laboratories Intl. stock?

CRL stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, DekaBank Deutsche Girozentrale, Massachusetts Financial Services Co. MA, BlackRock Inc., Great Lakes Advisors LLC, Russell Investments Group Ltd., Barclays PLC and Allianz Asset Management GmbH. Company insiders that have bought Charles River Laboratories Intl. stock in the last two years include Bradley Nixon Scharfe and Jason Wesley Scharfe. View Insider Buying and Selling for Charles River Laboratories Intl..

How do I buy shares of Charles River Laboratories Intl.?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Charles River Laboratories Intl.'s stock price today?

One share of CRL stock can currently be purchased for approximately $104.13.

How big of a company is Charles River Laboratories Intl.?

Charles River Laboratories Intl. has a market capitalization of $5.06 billion and generates $1.86 billion in revenue each year. The medical research company earns $123.35 million in net income (profit) each year or $5.27 on an earnings per share basis. Charles River Laboratories Intl. employs 11,800 workers across the globe.

How can I contact Charles River Laboratories Intl.?

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


MarketBeat Community Rating for Charles River Laboratories Intl. (CRL)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  339 (Vote Underperform)
Total Votes:  612
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Charles River Laboratories Intl. (NYSE:CRL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Charles River Laboratories Intl. in the last 12 months. Their average twelve-month price target is $115.7692, suggesting that the stock has a possible upside of 11.18%. The high price target for CRL is $130.00 and the low price target for CRL is $102.00. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.462.462.552.50
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $115.7692$115.7692$117.0909$104.5909
Price Target Upside: 11.18% upside9.22% upside6.79% upside3.16% upside

Charles River Laboratories Intl. (NYSE:CRL) Consensus Price Target History

Price Target History for Charles River Laboratories Intl. (NYSE:CRL)

Charles River Laboratories Intl. (NYSE:CRL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018Mitsubishi UFJ Financial GroupInitiated CoverageNeutral$115.00LowView Rating Details
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$94.00 ➝ $102.00LowView Rating Details
2/16/2018BarclaysReiterated RatingHold$110.00LowView Rating Details
2/15/2018Credit Suisse GroupReiterated RatingHold$108.00LowView Rating Details
2/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$110.00 ➝ $120.00MediumView Rating Details
2/14/2018SunTrust BanksUpgradeHold ➝ Buy$107.66 ➝ $125.00MediumView Rating Details
2/13/2018Royal Bank of CanadaSet Price TargetHold$116.00HighView Rating Details
2/13/2018Robert W. BairdSet Price TargetBuy$123.00HighView Rating Details
1/18/2018Evercore ISIInitiated CoverageIn ➝ In-Line$117.00LowView Rating Details
12/13/2017ArgusInitiated CoverageBuy ➝ Buy$120.00MediumView Rating Details
11/10/2017Bank of AmericaLower Price TargetBuy$117.00 ➝ $115.00N/AView Rating Details
10/9/2017Jefferies GroupBoost Price TargetBuy$120.00 ➝ $130.00N/AView Rating Details
6/28/2017CitigroupReiterated RatingNeutral$91.00 ➝ $104.00LowView Rating Details
2/15/2017UBSBoost Price Target$84.00N/AView Rating Details
12/16/2016Goldman Sachs GroupUpgradeSell ➝ Neutral$75.00 ➝ $77.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Charles River Laboratories Intl. (NYSE:CRL) Earnings History and Estimates Chart

Earnings by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Charles River Laboratories Intl. (NYSE:CRL) Earnings Estimates

2018 EPS Consensus Estimate: $5.64
2019 EPS Consensus Estimate: $6.50
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$1.24$1.29$1.26
Q2 20185$1.43$1.48$1.45
Q3 20185$1.38$1.47$1.42
Q4 20184$1.44$1.55$1.51
Q1 20191$1.50$1.50$1.50
Q2 20191$1.65$1.65$1.65
Q3 20191$1.64$1.64$1.64
Q4 20191$1.71$1.71$1.71

Charles River Laboratories Intl. (NYSE CRL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018$1.48N/AView Earnings Details
5/10/2018Q1 2018$1.26$1.38$480.03 million$493.97 millionViewN/AView Earnings Details
2/13/2018Q4 2017$1.26$1.40$475.02 million$478.50 millionViewListenView Earnings Details
11/9/2017Q3 2017$1.22$1.30$458.93 million$464.23 millionViewN/AView Earnings Details
8/9/2017Q2 2017$1.22$1.29$458.25 million$469.13 millionViewListenView Earnings Details
5/10/2017Q1 2017$1.1420$1.29$437.04 million$445.80 millionViewN/AView Earnings Details
2/14/2017Q416$1.11$1.21$441.64 million$466.80 millionViewListenView Earnings Details
11/2/2016Q316$1.13$1.18$291.20 million$425.70 millionViewListenView Earnings Details
8/3/2016Q216$1.10$1.20$425.05 million$434.10 millionViewListenView Earnings Details
5/4/2016Q116$0.90$0.98$354.92 million$354.90 millionViewListenView Earnings Details
2/10/2016Q415$0.94$1.00$349.20 million$353.90 millionViewListenView Earnings Details
11/4/2015Q315$0.94$1.03$340.09 million$349.50 millionViewListenView Earnings Details
7/30/2015Q215$0.97$0.96$338.30 million$339.60 millionViewListenView Earnings Details
4/29/2015Q115$0.82$0.79$324.00 million$320.40 millionViewListenView Earnings Details
2/10/2015Q414$0.71$0.81$318.73 million$329.50 millionViewListenView Earnings Details
10/29/2014Q314$0.80$0.86$326.70 million$327.60 millionViewListenView Earnings Details
8/6/2014Q214$0.82$0.97$327.96 million$341.18 millionViewListenView Earnings Details
4/30/2014Q114$0.74$0.82$302.08 million$299.40 millionViewListenView Earnings Details
2/12/2014Q413$0.68$0.73$289.56 million$289.20 millionViewListenView Earnings Details
10/30/2013Q313$0.70$0.79$290.28 million$292.10 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.71$0.73$293.77 million$294.40 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.71$0.69$294.53 million$291.20 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.60$0.64$280.81 million$280.10 millionViewListenView Earnings Details
10/30/2012$0.62$0.65ViewN/AView Earnings Details
8/7/2012$0.66$0.75ViewN/AView Earnings Details
5/2/2012$0.65$0.70ViewN/AView Earnings Details
2/13/2012$0.56$0.69ViewN/AView Earnings Details
11/1/2011$0.58$0.57ViewN/AView Earnings Details
8/2/2011$0.60$0.70ViewN/AView Earnings Details
5/3/2011$0.55$0.61ViewN/AView Earnings Details
2/8/2011$0.50$0.60ViewN/AView Earnings Details
11/3/2010Q3 2010$0.49$0.45ViewN/AView Earnings Details
8/2/2010Q2 2010$0.50$0.49ViewN/AView Earnings Details
4/26/2010Q1 2010$0.47$0.45ViewN/AView Earnings Details
2/8/2010Q4 2009$0.43$0.49ViewN/AView Earnings Details
11/3/2009Q3 2009$0.60$0.65ViewN/AView Earnings Details
8/4/2009Q2 2009$0.58$0.66ViewN/AView Earnings Details
5/5/2009Q1 2009$0.53$0.58ViewN/AView Earnings Details
2/9/2009Q4 2008$0.55$0.59ViewN/AView Earnings Details
11/5/2008Q3 2008$0.74$0.76ViewN/AView Earnings Details
8/5/2008Q2 2008$0.73$0.79ViewN/AView Earnings Details
5/6/2008Q1 2008$0.68$0.72ViewN/AView Earnings Details
2/11/2008Q4 2007$0.64$0.65ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Charles River Laboratories Intl. (NYSE:CRL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Charles River Laboratories Intl. (NYSE CRL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 97.76%
Insider Trading History for Charles River Laboratories Intl. (NYSE:CRL)
Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Charles River Laboratories Intl. (NYSE CRL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2018George MassaroDirectorSell1,218$107.19$130,557.4215,055View SEC Filing  
5/1/2018David Ross SmithInsiderSell945$104.23$98,497.3513,723View SEC Filing  
3/9/2018George M Milne JrDirectorSell7,740$115.00$890,100.0036,760View SEC Filing  
3/6/2018Birgit GirshickInsiderSell9,893$109.10$1,079,326.3026,470View SEC Filing  
3/6/2018James C FosterCEOSell24,008$110.00$2,640,880.00325,684View SEC Filing  
2/28/2018David Ross SmithCFOSell100$108.43$10,843.0013,103View SEC Filing  
2/28/2018James C FosterCEOSell3,372$107.39$362,119.08324,012View SEC Filing  
2/26/2018David Ross SmithInsiderSell3,868$107.35$415,229.8018,483View SEC Filing  
2/26/2018James C FosterCEOSell4,800$106.69$512,112.00306,914View SEC Filing  
2/21/2018William D BarboInsiderSell2,320$108.08$250,745.6021,276View SEC Filing  
2/16/2018David Ross SmithInsiderSell3,639$109.07$396,905.7315,110View SEC Filing  
2/15/2018James C FosterChairmanSell46$107.50$4,945.00292,621View SEC Filing  
2/15/2018Stephen D ChubbDirectorSell2,872$108.70$312,186.4036,461View SEC Filing  
1/18/2018Online Communications BdirectDirectorSell131,000$0.29$37,990.00
1/2/2018David Ross SmithInsiderSell5,486$109.53$600,881.58View SEC Filing  
1/2/2018James C FosterChairmanSell4,967$109.44$543,588.48329,928View SEC Filing  
1/2/2018Robert J BertoliniDirectorSell3,609$110.22$397,783.98View SEC Filing  
12/12/2017Kevin MaDirectorSell40,384$0.41$16,557.44
12/6/2017C Richard ReeseDirectorSell10,227$102.40$1,047,244.8051,444View SEC Filing  
11/10/2017Bradley Nixon ScharfeInsiderSell1,000,000$0.27$270,000.00
10/30/2017Bradley Nixon ScharfeInsiderBuy2,500$0.25$625.00
10/25/2017Bradley Nixon ScharfeInsiderBuy3,000$0.27$810.00
10/19/2017Bradley Nixon ScharfeInsiderBuy2,000$0.29$580.00
10/17/2017Bradley Nixon ScharfeInsiderBuy3,000$0.29$870.00
10/5/2017Davide MolhoInsiderSell6,165$110.00$678,150.00View SEC Filing  
9/5/2017Davide MolhoInsiderSell5,982$107.55$643,364.1022,714View SEC Filing  
8/17/2017William D BarboInsiderSell4,000$99.91$399,640.0020,424View SEC Filing  
8/14/2017David Ross SmithInsiderSell2,552$67.10$171,239.2011,671View SEC Filing  
7/17/2017George MassaroDirectorSell3,830$100.81$386,102.3018,731View SEC Filing  
7/10/2017James C FosterChairmanSell9,516$98.92$941,322.72361,171View SEC Filing  
6/22/2017Davide MolhoInsiderSell10,948$100.00$1,094,800.0027,497View SEC Filing  
6/22/2017James C FosterChairmanSell43,154$100.00$4,315,400.00361,178View SEC Filing  
6/8/2017David Ross SmithInsiderSell945$95.00$89,775.0014,203View SEC Filing  
5/26/2017Davide MolhoInsiderSell10,976$92.84$1,019,011.8427,525View SEC Filing  
5/23/2017Jason Wesley ScharfeDirectorSell10,000$0.31$3,100.00
5/17/2017Jason Wesley ScharfeDirectorSell10,000$0.34$3,400.00
5/12/2017George MassaroDirectorSell1,130$88.30$99,779.0015,831View SEC Filing  
5/11/2017Jason Wesley ScharfeDirectorSell6,000$0.36$2,160.00
5/10/2017Jason Wesley ScharfeDirectorSell9,000$0.36$3,240.00
3/29/2017Jason Wesley ScharfeDirectorSell10,000$0.34$3,400.00
3/16/2017Davide MolhoInsiderSell11,717$90.00$1,054,530.0028,266View SEC Filing  
3/10/2017David P JohstInsiderSell34,593$89.06$3,080,852.58201,005View SEC Filing  
3/6/2017William D BarboInsiderSell1,900$87.90$167,010.0022,224View SEC Filing  
3/3/2017David Ross SmithEVPSell3,890$88.12$342,786.8017,085View SEC Filing  
3/1/2017Robert J BertoliniDirectorSell5,255$87.53$459,970.1532,140View SEC Filing  
2/28/2017James C FosterChairmanSell4,910$87.09$427,611.90381,730View SEC Filing  
2/22/2017James C FosterChairmanSell9,717$87.64$851,597.88388,294View SEC Filing  
2/22/2017Jason Wesley ScharfeDirectorBuy15,000$0.29$4,350.00
2/21/2017Jason Wesley ScharfeDirectorBuy10,000$0.30$3,000.00
2/17/2017Jason Wesley ScharfeDirectorBuy10,000$0.30$3,000.00
2/15/2017Jason Wesley ScharfeDirectorBuy4,500$0.30$1,350.00
1/30/2017David P JohstInsiderSell13,950$78.00$1,088,100.00174,696View SEC Filing  
12/2/2016Stephen D ChubbDirectorSell4,564$71.57$326,645.4830,849View SEC Filing  
11/28/2016C Richard ReeseDirectorSell4,539$71.93$326,490.2744,943View SEC Filing  
8/30/2016Davide MolhoInsiderSell7,877$84.10$662,455.70View SEC Filing  
8/5/2016James C FosterChairmanSell18,351$85.63$1,571,396.13383,283View SEC Filing  
7/29/2016Richard F WallmanDirectorSell7,740$88.00$681,120.0024,190View SEC Filing  
7/1/2016George MassaroDirectorSell3,740$83.09$310,756.6018,935View SEC Filing  
5/24/2016John J CrowleyCAOSell1,913$85.00$162,605.006,883View SEC Filing  
5/13/2016Richard F WallmanDirectorSell1,970$82.32$162,170.4017,690View SEC Filing  
5/10/2016Richard F WallmanDirectorSell11,990$84.00$1,007,160.0027,420View SEC Filing  
5/9/2016George MassaroDirectorSell985$82.17$80,937.4513,020View SEC Filing  
5/6/2016Richard F WallmanDirectorSell2,720$81.00$220,320.0015,430View SEC Filing  
4/6/2016Davide MolhoVPSell30,667$80.00$2,453,360.0079,008View SEC Filing  
3/2/2016Nancy GillettVPSell7,015$75.00$526,125.0023,809View SEC Filing  
2/29/2016Nancy GillettVPSell3,646$73.50$267,981.0021,953View SEC Filing  
2/25/2016David P JohstVPSell34,075$73.02$2,488,156.50189,023View SEC Filing  
2/24/2016James C FosterCEOSell3,873$70.40$272,659.20402,707View SEC Filing  
2/23/2016George M Milne JrDirectorSell10,440$73.02$762,328.8038,200View SEC Filing  
2/22/2016James C FosterCEOSell9,831$73.12$718,842.72402,964View SEC Filing  
2/12/2016C Richard ReeseDirectorSell4,228$71.48$302,217.4431,123View SEC Filing  
2/12/2016Nancy GillettVPSell6,750$71.90$485,325.0025,392View SEC Filing  
2/1/2016Stephen D ChubbDirectorSell2,000$74.76$149,520.0011,504View SEC Filing  
12/17/2015George MassaroDirectorSell7,740$80.00$619,200.0013,120View SEC Filing  
12/17/2015Thomas F. AckermaninsiderSell10,000$80.00$800,000.00100,635View SEC Filing  
11/19/2015Thomas F. AckermaninsiderSell10,000$75.00$750,000.00100,635View SEC Filing  
11/4/2015Thomas F. AckermaninsiderSell21,612$70.01$1,513,056.12100,635View SEC Filing  
11/2/2015Stephen D ChubbDirectorSell2,000$66.57$133,140.0013,504View SEC Filing  
8/17/2015Thomas F AckermanInsiderSell5,000$75.53$377,650.00View SEC Filing  
5/15/2015Thomas F AckermanCFOSell3,900$70.51$274,989.00View SEC Filing  
5/7/2015George MassaroDirectorSell1,360$70.21$95,485.60View SEC Filing  
3/3/2015Stephen D ChubbDirectorSell2,000$75.52$151,040.00View SEC Filing  
3/2/2015Deborah Turner KochevarDirectorSell2,600$76.59$199,134.00View SEC Filing  
3/2/2015James C FosterCEOSell2,036$76.93$156,629.48View SEC Filing  
3/2/2015Nancy GillettVPSell4,379$76.72$335,956.88View SEC Filing  
2/27/2015Nancy GillettVPSell2,772$76.95$213,305.40View SEC Filing  
2/25/2015James C FosterCEOSell4,621$75.96$351,011.16View SEC Filing  
2/25/2015Nancy GillettVPSell5,015$76.12$381,741.80View SEC Filing  
2/24/2015James C FosterCEOSell4,800$75.70$363,360.00View SEC Filing  
2/24/2015Jorg GellerVPSell12,061$76.17$918,686.37View SEC Filing  
2/23/2015James C FosterCEOSell8,423$76.56$644,864.88View SEC Filing  
2/23/2015Jorg GellerVPSell7,041$76.59$539,270.19View SEC Filing  
2/20/2015George M Milne JrDirectorSell6,000$75.87$455,220.00View SEC Filing  
2/19/2015James C FosterCEOSell9,671$75.00$725,325.00View SEC Filing  
2/18/2015Stephen D ChubbDirectorSell5,011$73.97$370,663.67View SEC Filing  
2/17/2015Jorg GellerVPSell14,430$73.54$1,061,182.20View SEC Filing  
2/17/2015Thomas F AckermanCFOSell4,400$73.50$323,400.00View SEC Filing  
2/13/2015Davide MolhoVPSell19,075$74.00$1,411,550.00View SEC Filing  
2/12/2015Jorg GellerVPSell8,458$73.68$623,185.44View SEC Filing  
1/26/2015Thomas F AckermanCFOSell10,000$70.00$700,000.00View SEC Filing  
1/8/2015David P JohstVPSell4,737$67.00$317,379.00View SEC Filing  
1/7/2015David P JohstVPSell26,100$65.00$1,696,500.00View SEC Filing  
12/1/2014Stephen D ChubbDirectorSell2,000$64.44$128,880.00View SEC Filing  
11/28/2014David P JohstVPSell6,982$65.34$456,203.88View SEC Filing  
11/17/2014Thomas F AckermanCFOSell10,000$63.70$637,000.00View SEC Filing  
11/14/2014Jorg GellerVPSell5,610$63.57$356,627.70View SEC Filing  
11/6/2014C Richard ReeseDirectorSell5,849$63.39$370,768.11View SEC Filing  
11/4/2014John J CrowleyCAOSell1,000$64.00$64,000.00View SEC Filing  
11/3/2014Davide MolhoVPSell16,402$64.54$1,058,585.08View SEC Filing  
11/3/2014George MassaroDirectorSell16,710$65.00$1,086,150.00View SEC Filing  
11/3/2014Thomas F AckermanCFOSell36,100$65.00$2,346,500.00View SEC Filing  
10/30/2014Nancy GillettVPSell1,069$65.00$69,485.00View SEC Filing  
10/28/2014David P JohstVPSell74,780$64.00$4,785,920.00View SEC Filing  
10/3/2014James C FosterCEOSell136,647$62.00$8,472,114.00View SEC Filing  
9/29/2014Thomas F AckermanCFOSell5,000$60.00$300,000.00View SEC Filing  
9/4/2014Davide MolhoVPSell4,900$61.34$300,566.00View SEC Filing  
9/2/2014Stephen D ChubbDirectorSell2,000$59.18$118,360.00View SEC Filing  
8/26/2014George MassaroDirectorSell10,440$60.00$626,400.00View SEC Filing  
8/18/2014Thomas F AckermanCFOSell23,156$59.25$1,371,993.00View SEC Filing  
8/12/2014Richard F WallmanDirectorSell3,240$58.20$188,568.00View SEC Filing  
6/2/2014Stephen D ChubbDirectorSell2,000$52.93$105,860.00View SEC Filing  
5/22/2014Deborah Turner KochevarDirectorSell3,100$53.30$165,230.0011,370View SEC Filing  
5/8/2014George MassaroDirectorSell1,620$52.70$85,374.0016,510View SEC Filing  
5/5/2014Thomas AckermanCFOSell5,430$50.76$275,626.80113,781View SEC Filing  
3/7/2014Nancy GillettVPSell10,110$58.36$590,019.6038,515View SEC Filing  
3/4/2014Nancy GillettVPSell13,650$58.98$805,077.0048,625View SEC Filing  
3/3/2014Stephen ChubbDirectorSell2,000$58.70$117,400.0023,645View SEC Filing  
2/28/2014Jorg GellerVPSell7,486$59.41$444,743.2655,722View SEC Filing  
2/27/2014Nancy GillettVPSell4,000$60.00$240,000.0043,162View SEC Filing  
2/25/2014Jorg GellerVPSell3,188$58.49$186,466.1250,235View SEC Filing  
2/20/2014Nancy GillettVPSell4,000$58.96$235,840.0050,510View SEC Filing  
2/19/2014Stephen ChubbDirectorSell5,198$58.35$303,303.3025,645View SEC Filing  
2/18/2014Thomas AckermanCFOSell14,000$58.05$812,700.00105,539View SEC Filing  
1/13/2014David JohstVPSell19,750$58.00$1,145,500.00141,799View SEC Filing  
1/7/2014George MassaroDirectorSell5,750$54.00$310,500.0015,410View SEC Filing  
12/20/2013Thomas AckermanCFOSell5,000$52.72$263,600.00107,689View SEC Filing  
12/4/2013Jorg GellerVPSell7,200$51.93$373,896.0054,192View SEC Filing  
12/2/2013Stephen ChubbDirectorSell2,000$51.92$103,840.0026,843View SEC Filing  
9/16/2013George MassaroDirectorSell5,958$47.38$282,290.0415,410View SEC Filing  
9/9/2013James C FosterCEOSell174,479$47.00$8,200,513.00View SEC Filing  
9/4/2013Thomas F AckermanCFOSell6,100$46.13$281,393.00View SEC Filing  
9/3/2013Stephen ChubbDirectorSell2,000$46.49$92,980.0028,843View SEC Filing  
8/29/2013James FosterCEOSell40,983$47.00$1,926,201.00366,580View SEC Filing  
8/22/2013Davide MolhoVPSell6,500$47.93$311,545.0040,892View SEC Filing  
8/20/2013Stephen ChubbDirectorSell4,000$47.46$189,840.0030,843View SEC Filing  
8/5/2013Jorg GellerVPSell3,025$46.38$140,299.5055,085View SEC Filing  
8/5/2013Richard WallmanDirectorSell1,500$45.95$68,925.0016,700View SEC Filing  
8/2/2013Davide MolhoVPSell4,100$45.89$188,149.0040,892View SEC Filing  
8/2/2013Deborah Turner KochevarDirectorSell4,447$46.02$204,650.9413,870View SEC Filing  
8/2/2013Thomas AckermanCFOSell26,250$46.03$1,208,287.50105,039View SEC Filing  
6/3/2013Thomas F AckermanCFOSell4,000$42.40$169,600.00View SEC Filing  
5/14/2013James C FosterCEOSell113,810$45.00$5,121,450.00View SEC Filing  
5/10/2013George MassaroDirectorSell2,020$44.09$89,061.80View SEC Filing  
3/13/2013David P JohstVPSell17,038$45.00$766,710.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Charles River Laboratories Intl. (NYSE CRL) News Headlines

Source:
DateHeadline
Charles River Laboratories Intl. Inc (CRL) Given Average Rating of "Buy" by AnalystsCharles River Laboratories Intl. Inc (CRL) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 24 at 10:55 AM
$569.87 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter$569.87 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter
www.americanbankingnews.com - May 21 at 4:16 AM
$1.47 Earnings Per Share Expected for Charles River Laboratories (CRL) This Quarter$1.47 Earnings Per Share Expected for Charles River Laboratories (CRL) This Quarter
www.americanbankingnews.com - May 19 at 11:05 AM
Charles River Laboratories Forecasted to Post Q2 2018 Earnings of $1.46 Per Share (CRL)Charles River Laboratories Forecasted to Post Q2 2018 Earnings of $1.46 Per Share (CRL)
www.americanbankingnews.com - May 18 at 8:14 AM
Charles River Laboratories (CRL) Forecasted to Earn Q3 2018 Earnings of $1.47 Per ShareCharles River Laboratories (CRL) Forecasted to Earn Q3 2018 Earnings of $1.47 Per Share
www.americanbankingnews.com - May 17 at 8:10 AM
Charles River Laboratories (CRL) to Post Q2 2018 Earnings of $1.45 Per Share, SunTrust Banks ForecastsCharles River Laboratories (CRL) to Post Q2 2018 Earnings of $1.45 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - May 17 at 6:34 AM
Charles River Laboratories (CRL) Sees Large Drop in Short InterestCharles River Laboratories (CRL) Sees Large Drop in Short Interest
www.americanbankingnews.com - May 17 at 3:16 AM
Charles River Laboratories (CRL) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - SlideshowCharles River Laboratories (CRL) Presents At Bank of America Merrill Lynch 2018 Healthcare Conference - Slideshow
seekingalpha.com - May 16 at 4:55 PM
Zacks Investment Research Lowers Charles River Laboratories (CRL) to HoldZacks Investment Research Lowers Charles River Laboratories (CRL) to Hold
www.americanbankingnews.com - May 15 at 8:14 PM
George Massaro Sells 1,218 Shares of Charles River Laboratories (CRL) StockGeorge Massaro Sells 1,218 Shares of Charles River Laboratories (CRL) Stock
www.americanbankingnews.com - May 15 at 4:18 PM
Charles River Laboratories (CRL) versus National Research (NRCIB) Head-To-Head SurveyCharles River Laboratories (CRL) versus National Research (NRCIB) Head-To-Head Survey
www.americanbankingnews.com - May 14 at 5:25 AM
Charles River Laboratories (CRL) Forecasted to Post FY2019 Earnings of $6.56 Per ShareCharles River Laboratories (CRL) Forecasted to Post FY2019 Earnings of $6.56 Per Share
www.americanbankingnews.com - May 14 at 4:47 AM
Charles River Laboratories (CRL) Rating Increased to B+ at TheStreetCharles River Laboratories (CRL) Rating Increased to B+ at TheStreet
www.americanbankingnews.com - May 12 at 7:35 AM
Charles River Laboratories (CRL) Rating Increased to Buy at Zacks Investment ResearchCharles River Laboratories (CRL) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 11 at 8:33 PM
First Week of November 16th Options Trading For Charles River Laboratories International (CRL)First Week of November 16th Options Trading For Charles River Laboratories International (CRL)
www.nasdaq.com - May 11 at 4:59 PM
Edited Transcript of CRL earnings conference call or presentation 10-May-18 12:30pm GMTEdited Transcript of CRL earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 9:41 AM
Charles River Laboratories International (CRL) Q1 2018 Results - Earnings Call TranscriptCharles River Laboratories International (CRL) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:05 PM
Charles River Laboratories (CRL) Posts  Earnings Results, Beats Expectations By $0.12 EPSCharles River Laboratories (CRL) Posts Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - May 10 at 3:32 PM
Charles River Laboratories International Inc. Q1 adjusted earnings Beat EstimatesCharles River Laboratories International Inc. Q1 adjusted earnings Beat Estimates
www.nasdaq.com - May 10 at 9:09 AM
Charles River Labs Q1 top line up 11%; earnings up 13%; cash flow up 77%Charles River Labs Q1 top line up 11%; earnings up 13%; cash flow up 77%
seekingalpha.com - May 10 at 9:09 AM
Charles River Laboratories Q1 Results Beat View; Lifts 2018 Adj. EPS ViewCharles River Laboratories Q1 Results Beat View; Lifts 2018 Adj. EPS View
www.nasdaq.com - May 10 at 9:09 AM
Charles River: 1Q Earnings SnapshotCharles River: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:09 AM
Charles River Laboratories (CRL) Issues FY18 Earnings GuidanceCharles River Laboratories (CRL) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 10 at 8:58 AM
Should You Buy Charles River Laboratories (CRL) Before Earnings?Should You Buy Charles River Laboratories (CRL) Before Earnings?
www.zacks.com - May 9 at 9:05 AM
David Ross Smith Sells 945 Shares of Charles River Laboratories (CRL) StockDavid Ross Smith Sells 945 Shares of Charles River Laboratories (CRL) Stock
www.americanbankingnews.com - May 3 at 10:29 AM
Charles River Laboratories Announces Extended Relationship with The Michael J. Fox FoundationCharles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation
finance.yahoo.com - May 3 at 8:58 AM
Charles River Laboratories (CRL) Expected to Post Quarterly Sales of $480.54 MillionCharles River Laboratories (CRL) Expected to Post Quarterly Sales of $480.54 Million
www.americanbankingnews.com - May 3 at 2:12 AM
Zacks: Brokerages Anticipate Charles River Laboratories (CRL) to Announce $1.26 EPSZacks: Brokerages Anticipate Charles River Laboratories (CRL) to Announce $1.26 EPS
www.americanbankingnews.com - May 1 at 9:10 PM
Charles River Laboratories Expands Services for Early Discovery ScreeningCharles River Laboratories Expands Services for Early Discovery Screening
finance.yahoo.com - May 1 at 9:04 AM
Charles River Laboratories (CRL) Scheduled to Post Earnings on TuesdayCharles River Laboratories (CRL) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 3:21 AM
Charles River Laboratories (CRL) Given Consensus Rating of "Buy" by AnalystsCharles River Laboratories (CRL) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 29 at 9:38 AM
Analyzing Charles River Laboratories (CRL) and Anavex Life Sciences (AVXL)Analyzing Charles River Laboratories (CRL) and Anavex Life Sciences (AVXL)
www.americanbankingnews.com - April 27 at 1:38 PM
Jefferies Group Comments on Charles River Laboratories Q1 2018 Earnings (CRL)Jefferies Group Comments on Charles River Laboratories' Q1 2018 Earnings (CRL)
www.americanbankingnews.com - April 26 at 8:24 AM
Charles River Laboratories (CRL) versus National Research (NRCIB) Head-To-Head ContrastCharles River Laboratories (CRL) versus National Research (NRCIB) Head-To-Head Contrast
www.americanbankingnews.com - April 24 at 7:24 PM
Charles River Laboratories (CRL) Research Coverage Started at Mitsubishi UFJ Financial GroupCharles River Laboratories (CRL) Research Coverage Started at Mitsubishi UFJ Financial Group
www.americanbankingnews.com - April 20 at 10:25 AM
Charles River Laboratories International Breaks Below 200-Day Moving Average - Notable for CRLCharles River Laboratories International Breaks Below 200-Day Moving Average - Notable for CRL
www.nasdaq.com - April 20 at 9:09 AM
National Research (NRCIB) & Charles River Laboratories (CRL) Head-To-Head ContrastNational Research (NRCIB) & Charles River Laboratories (CRL) Head-To-Head Contrast
www.americanbankingnews.com - April 19 at 3:26 AM
Charles River Laboratories (CRL) Rating Reiterated by BarclaysCharles River Laboratories (CRL) Rating Reiterated by Barclays
www.americanbankingnews.com - April 17 at 4:47 PM
$481.32 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter$481.32 Million in Sales Expected for Charles River Laboratories (CRL) This Quarter
www.americanbankingnews.com - April 16 at 2:13 AM
Charles River Laboratories (CRL) Rating Lowered to Buy at BidaskClubCharles River Laboratories (CRL) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 11:27 PM
Zacks: Brokerages Anticipate Charles River Laboratories (CRL) Will Post Earnings of $1.26 Per ShareZacks: Brokerages Anticipate Charles River Laboratories (CRL) Will Post Earnings of $1.26 Per Share
www.americanbankingnews.com - April 14 at 9:10 PM
Charles River Laboratories Schedules First-Quarter 2018 Earnings Release and Conference CallCharles River Laboratories Schedules First-Quarter 2018 Earnings Release and Conference Call
finance.yahoo.com - April 12 at 4:54 PM
Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018
finance.yahoo.com - April 10 at 9:23 AM
Charles River to invest in next-gen sequencing outfit PathoQuestCharles River to invest in next-gen sequencing outfit PathoQuest
seekingalpha.com - April 9 at 9:12 AM
Contrasting Luna Innovations (LUNA) and Charles River Laboratories (CRL)Contrasting Luna Innovations (LUNA) and Charles River Laboratories (CRL)
www.americanbankingnews.com - April 9 at 3:13 AM
Charles River Laboratories (CRL) Rating Reiterated by Jefferies GroupCharles River Laboratories (CRL) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 8 at 11:23 PM
Charles River Laboratories (CRL) Stock Rating Lowered by ValuEngineCharles River Laboratories (CRL) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 7 at 10:27 AM
Charles River Laboratories (CRL) Receives Average Recommendation of "Buy" from AnalystsCharles River Laboratories (CRL) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 10:44 AM
Charles River Laboratories Announces Closing of Senior Notes OfferingCharles River Laboratories Announces Closing of Senior Notes Offering
finance.yahoo.com - April 3 at 9:14 AM
Charles River Laboratories Completes the Acquisition of MPI ResearchCharles River Laboratories Completes the Acquisition of MPI Research
finance.yahoo.com - April 3 at 9:14 AM

SEC Filings

Charles River Laboratories Intl. (NYSE:CRL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Charles River Laboratories Intl. (NYSE:CRL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Charles River Laboratories Intl. (NYSE CRL) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.